Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q1 2022 Earnings Conference Call May 4, 2022 5:00 PM ET

Company Participants

Christine Cassiano - Chief Communications Officer

David Chang - President and Chief Executive Officer

Rafael Amado - EVP of Research and Development and Chief Medical Officer

Eric Schmidt - Chief Financial Officer

Conference Call Participants

Tyler Van Buren - Cowen

Cory Kasimov - JP Morgan

Salveen Richter - Goldman Sachs

John Newman - Canaccord

Luca Issi - RBC Capital

Kalpit Patel - B. Riley

Anand Sankar - Truist

Raju Prasad - William Blair

Dane Leone - Raymond James

Operator

Thank you for standing by, and Welcome to Allogene Therapeutics First Quarter 2022 Conference Call [Operator Instructions].

I would now like to turn the call over to Christine Cassiano, Chief Communications Officer. Please go ahead.

Christine Cassiano

Thank you, operator, and welcome to all who have joined this call. After the market closed today, Allogene issued a press release that provides a business update and financial results for the first quarter of 2022. This press release and today's webcast are both available on our Web site. As a reminder for this call, we ask that all keep their questions to one per person. Joining me on the call today are Dr. David Chang, President and Chief Executive Officer; Dr. Rafael Amado, Executive Vice President of Research and Development and Chief Medical Officer; and Dr. Eric Schmidt, Chief Financial Officer.

During today's call, we will be making certain forward-looking statements. These may include statements regarding the success and timing of our ongoing advance clinical trials, data presentations, regulatory filings, future research and development efforts, manufacturing capabilities and 2022 financial guidance, among other things. These forward-looking statements are based on current information, assumptions and expectations that are subject to change. A description of potential risks can be found in our earnings press release and latest SEC disclosure documents. You are cautioned not to place undue reliance on these forward-looking statements, and Allogene disclaims any obligation to update these statements.

I'll now turn the call over to David.

David Chang

Thank you, Christine, and good afternoon. This month marks the fourth anniversary of Allogene‘s Inception. We founded Allogene with a belief that for cell therapy to truly change the landscape, it would need to be industrialized. Today, as we report on the first quarter of 2022, I am immensely proud of all we have accomplished in the last four years. This includes delivering proof of concept data from our CD-19 and BCMA programs that is differentiated in the field, including the most comprehensive set of Allogene CAR-T allogeneic data demonstrating durability, as well as operationalizing Cell Forge 1.